LaunchTrends: Anoro Ellipta Wave 2 is the second of a three-wave report series designed to track the postlaunch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. This syndicated primary research report examines physicians’ perception at six months following the commercial availability of Anoro Ellipta. The report also investigates where Anoro Ellipta will fit into the treatment algorithm, likely patient candidates, perceived advantages and disadvantages of the product, and GlaxoSmithKline’s promotional efforts.
Questions Answered in This Report:
- At six months postlaunch of Anoro Ellipta, both aided and unaided familiarity and awareness have increased among U.S. pulmonologists. How much has physician prescribing increased after more familiarity with the agent, and in how many new patients do physicians anticipate starting the drug in the next month?
- Pulmonologists are choosing to prescribe Anoro Ellipta in certain disease severities and a specific line of therapy. Of the patients for whom pulmonologists have prescribed Anoro Ellipta, how many are classified as GOLD 1, 2, 3 or 4?
- Anoro Ellipta is competing strongly with certain agents placing these agents most at risk of being replaced by Anoro Ellipta. What percentage of COPD patients who are likely candidates for Anoro Ellipta would be new starts, would add Anoro Ellipta to regimen with no changes to original regimen, would add Anoro Ellipta to regimen but replace another product in the regimen, or switch from a specific regimen to solely Anoro Ellipta?
Markets covered: United States.
Primary research: 74 board-certified U.S. pulmonologists, currently in clinical practice treating a minimum of 50 COPD patients; 10 follow-up qualitative interviews with U.S. pulmonologists.
Methodology: 30-minute online quantitative survey fielded six months after the launch of Anoro Ellipta for COPD.
Emerging therapies: Phase III: 2 drugs; preregistration: 2 drugs.